RAYOPIQ Trademark

Trademark Overview

On Wednesday, September 11, 2019, a trademark application was filed for RAYOPIQ with the United States Patent and Trademark Office. The USPTO has given the RAYOPIQ trademark a serial number of 88613530. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 11, 2022. This trademark is owned by Allergan Development Ventures I, L.P.. The RAYOPIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of macular degeneration
rayopiq

General Information

Serial Number88613530
Word MarkRAYOPIQ
Filing DateWednesday, September 11, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 11, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 14, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of macular degeneration

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 20, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAllergan Development Ventures I, L.P.
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressHamilton HM12
BM
Party NameAllergan Development Ventures I, L.P.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressHamilton HM12
BM

Trademark Events

Event DateEvent Description
Monday, April 11, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 11, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, February 25, 2022ASSIGNED TO EXAMINER
Thursday, August 12, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 10, 2021EXTENSION 3 GRANTED
Tuesday, August 10, 2021EXTENSION 3 FILED
Tuesday, August 10, 2021TEAS EXTENSION RECEIVED
Tuesday, August 3, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 3, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, August 3, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 22, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 11, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 9, 2021EXTENSION 2 GRANTED
Tuesday, February 9, 2021EXTENSION 2 FILED
Tuesday, February 9, 2021TEAS EXTENSION RECEIVED
Friday, September 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 2, 2020EXTENSION 1 GRANTED
Wednesday, September 2, 2020EXTENSION 1 FILED
Wednesday, September 2, 2020TEAS EXTENSION RECEIVED
Tuesday, March 10, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 14, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 14, 2020PUBLISHED FOR OPPOSITION
Wednesday, December 25, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, December 12, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 11, 2019ASSIGNED TO EXAMINER
Friday, October 18, 2019TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Friday, October 18, 2019TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, September 20, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, September 14, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

rayopiq degeneration macular treatment preparations pharmaceutical